Somehow I don't think their problems are over. Who is this "forensic investigator"? Very secretive. Sounds suspicious, like an insider. "Big four"?? who?
I understand why some may have (past tense) thought this was a good stock to short. But Outerwall is diversifying AND there is a larger segment of the population that still needs an option to streaming.
Yes, most of us middle - upper class are willing to pay $120-200/mos for cable and internet. But there are many families that have low cost cable/satelite with no add ons and need a movie option. Redbox won't go away soon and their other businesses are doing just fine.
PE and PEG says buy buy buy. Or cover cover cover.!!
12-15 is not a reasonable level for a growth stock. PE range of 25-35 is reasonable.
The float is about 36M...institutions own about 2.5Million shares (6.6%)
The avg trading volume is 336,00 and today's volume so far is 5,300,000.
It is not hard to see what is happening. Institutions are selling a typically low volume stock this morning driving this down sharply. It will take a while to recover. THere is value here at these levels , but this morning if you are buying you are swimming into a strong current.
I agree. Its shorts who are yelling pump and dump. Why would anyone care otherwise. Shorts are definitely at risk tomorrow morning.
I agree with retracing, but the other way. It will retrace it way back to .90+, were it was in January. TRKK will be back up to its previous reading range before the last 4 month fall. Then we can see where it goes from there.
David Phipps, Chief Executive Officer of Orbital Tracking Corp. "As now being demonstrated in our financial results, our continued growth in product sales is producing a meaning shift in our business, one towards higher-margin, recurring revenue based on airtime usage from our growing customer base. Looking ahead to the remainder of 2016, we have reason to be optimistic that demand for our products remain strong and that top line revenue will to grow while margins continue to improve."
I get it. not a good quarter...again. But I am shocked that a lot of this hasn't been baked in already.
Bad, yes. But a 25% walloping AH?? wow, I am not sure that the baby is not being thrown out with the bath water here. Parts of Endo's business are worth more than this. (sum of parts are greater than the whole).
I am an AH Buyer. I know it can get worse in the AM, but this is pretty extreme given that a revenue/EPS reduction should have been expected.
Ok, you got me to read your article. Nice thorough job of providing a primer for us laymen on drug labling and KMPH's prospects.
Finally a positive sign....
"The man in charge of Mirati Therapeutics Inc. (NASDAQ:MRTX) also bought a sizable block of shares earlier this week. President and CEO Charles M. Baum purchased 20,000 shares on Tuesday at prices that ranged from $6.96 to $7.14 per share, boosting his ownership to 48,556 shares."
This may impact earnings a little, but overall a very healthy sign. This has been a pretty volatile stock due to its low float. But with its very low PE and PEG, $81 looks like a great entry point.
LOL you jump on a typo...how pathetic. Proellex is also good to help shorts stop their bleeding tomorrow.
You can short stocks under $5 and YES you can short OTC and Pink Sheet stocks. Not all brokers allow it though.
So get your facts right before name calling. OR are you just a short. Come on,... screaming dilution and other P&D. Douth protest too much. Hmmm....
I am guessing institutional selling is the reason for the pressure this morning. Not sure when institutional selling will subside,
Not only is TRKK way above daily volume, but the bid/ask volume size is crazy high!!
Interest right now is intense! .20 looks like the launching point.!
When you look at the revenue miss of 572M versus 596M estimate, it doesn't look that huge. Except they were expected to easily beat expectations. AND they are trading at a forward PE of 41 with a PEG of 2.72.
This will not be met favorably tomorrow morning. Especially since we will all have to wait until May 3rd for EPS forecast.
- RG-101, a GalNAc-conjugated anti-miR targeting miR-122 to treat patients with hepatitis C virus infection;
- RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome; and
- RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107 to treat nonalcoholic steatohepatitis in patients with type 2 diabetes/pre-diabetes.
The company has strategic alliances with:
- GSK to discover and develop microRNA therapeutics for immuno-inflammatory diseases;
- Sanofi to discover and develop microRNA therapeutics for fibrotic diseases;
- AstraZeneca AB to discover and develop microRNA therapeutics for cardiovascular diseases, metabolic diseases, and oncology; and
- Biogen Inc. to evaluate the use of microRNA signatures as a biomarker for human patients with various sclerosis.
touché 8*), though I am not sure I am worthy of looking up past messages. Thanks anyway